Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURE: Methotrexate in Recurrent dVIN
2025-524373-17-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in differentiated vulvar intraepithelial neoplasia (dVIN) and Kraurosis vulvae, sponsored by Amsterdam University Medical Center. Primary endpoints: dVIN recurrence rate with and without methotrexate and Time to recurrence of dVIN. Planned start Aug 2026; status: authorised.
02
Drugs
methotrexate
03
Conditions
differentiated vulvar intraepithelial neoplasia (dVIN)Kraurosis vulvae
Beyond the preview
Go deeper on 2025-524373-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524373-17-00.